참고문헌
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589. https://doi.org/10.1056/NEJMoa0806470
- Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. https://doi.org/10.1056/NEJMoa0802743
- ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. https://doi.org/10.1056/NEJMoa0802987
- Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139. https://doi.org/10.1056/NEJMoa0808431
- Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-559. https://doi.org/10.7326/0003-4819-154-8-201104190-00007
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149. https://doi.org/10.2337/dc14-2441
- Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154. https://doi.org/10.1056/NEJMoa1212914
- Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med 2015;163:848-860. https://doi.org/10.7326/M15-1400
- Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012. https://doi.org/10.1001/jama.281.21.2005
- Ko SH, Hur KY, Rhee SY, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J 2017;41:347-348.
- The Korea National Diabetes Program (KNDP) Investigators. Clinical Practice Guideline for the Prevention and Management of Diabetes in Korea. Seoul (KR): Medbook, 2014.
- Korean Diabetes Association. 2015 Treatment Guidelines for Diabetes. Seoul (KR): Korean Diabetes Association, 2015.
- American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Suppl 1):S64-S74. https://doi.org/10.2337/dc17-S011
- McGuire H, Longson D, Adler A, Farmer A, Lewin I; Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ 2016;353:i1575.
- International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014;104:1-52. https://doi.org/10.1016/j.diabres.2012.10.001
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Harper W, Clement M, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37 Suppl 1:S61-S68.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2017 executive summary. Endocr Pract 2017;23:207-238. https://doi.org/10.4158/EP161682.CS
- Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137-2139. https://doi.org/10.2337/dc06-1120
- Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010;33:1859-1864. https://doi.org/10.2337/dc09-1727
- Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-885. https://doi.org/10.2337/diacare.26.3.881
- Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001;44:2107-2114. https://doi.org/10.1007/s001250100020
- Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-621. https://doi.org/10.1016/S0140-6736(98)12131-1
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
- Goldberg RB, Aroda VR, Bluemke DA, et al. Effect of longterm metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium. Circulation 2017;136:52-64. https://doi.org/10.1161/CIRCULATIONAHA.116.025483
- Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613. https://doi.org/10.7326/0003-4819-154-9-201105030-00336
- Chan JC, Deerochanawong C, Shera AS, et al. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective. Diabetes Res Clin Pract 2007;75:255-266. https://doi.org/10.1016/j.diabres.2006.06.023
- Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-751. https://doi.org/10.7326/M15-2650
- Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313-324. https://doi.org/10.1001/jama.2016.9400
- Yoon KH, Shin JA, Kwon HS, et al. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011;35:26-33. https://doi.org/10.4093/dmj.2011.35.1.26
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 2016;101:1754-1761. https://doi.org/10.1210/jc.2015-3754
- Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708. https://doi.org/10.1007/s00125-012-2827-3
- Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326. https://doi.org/10.1056/NEJMoa1307684
- White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335. https://doi.org/10.1056/NEJMoa1305889
- Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242. https://doi.org/10.1056/NEJMoa1501352
- Abbas AS, Dehbi HM, Ray KK. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes Metab 2016;18:295-299. https://doi.org/10.1111/dom.12595
- Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol 2016;211:88-95. https://doi.org/10.1016/j.ijcard.2016.02.146
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. https://doi.org/10.1056/NEJMoa1504720
- Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 2017;54:19-36. https://doi.org/10.1007/s00592-016-0892-7
- Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from EMPA-REG OUTCOME((R)). Circ J 2017;81:227-234. https://doi.org/10.1253/circj.CJ-16-1148
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657. https://doi.org/10.1056/NEJMoa1611925
- Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitao C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016;13:e1001992. https://doi.org/10.1371/journal.pmed.1001992
- Kim SY, Kim HJ, Han KA, et al. Efficacy and safety of mitiglinide in Korean type 2 diabetic patients: prospective randomised multicenter comparative phase III study. J Korean Diabetes Assoc 2007;31:163-174. https://doi.org/10.4093/jkda.2007.31.2.163
-
Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of
${\alpha}$ -glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother 2015;16:1959-1981. https://doi.org/10.1517/14656566.2015.1070827 - Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-1289. https://doi.org/10.1016/S0140-6736(05)67528-9
- Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188. https://doi.org/10.1001/jama.298.10.1180
- Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-935. https://doi.org/10.7326/0003-4819-121-12-199412150-00004
- Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17:561-566. https://doi.org/10.2337/diacare.17.6.561
- Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22:960-964. https://doi.org/10.2337/diacare.22.6.960
- Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD004654.
- Chin SO, Rhee SY, Chon S, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract 2016;122:54-61. https://doi.org/10.1016/j.diabres.2016.09.027
- Rhee SY, Hong SM, Chon S, et al. Hypoglycemia and medical expenses in patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. PLoS One 2016;11:e0148630. https://doi.org/10.1371/journal.pone.0148630
- Cha SA, Yun JS, Lim TS, et al. Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J 2016;40:202-210. https://doi.org/10.4093/dmj.2016.40.3.202
- Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J 2016;40:423-432. https://doi.org/10.4093/dmj.2016.40.6.423
피인용 문헌
- Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis vol.42, pp.2, 2018, https://doi.org/10.4093/dmj.2018.42.2.93
- Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study vol.14, pp.2, 2019, https://doi.org/10.1371/journal.pone.0211959
- Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes vol.42, pp.4, 2017, https://doi.org/10.4082/kjfm.19.0161